R & D

Regarding the Press Release Issued on February 17 related to Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) for Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

 This material is intended to notify the statement on the following correction and replacement regarding the press release issued on February 17, 2023. The statement was made on April 24 (local time) by Bristol Myers Squibb, our license partner for Opdivo and Exelixis.

CORRECTED and REPLACING: Minor updates were made on April 24, 2023, to correct an error in the original data analysis impacting the blinded independent central reviewer (BICR)-assessed data points (PFS, ORR, and DoR). The safety and efficacy profile, including the OS data, was not affected and the data updates should not impact patient care.